|
1) Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myelo-proliferative disorders. N Engl J Med. 2005; 352: 1779-90
|
|
|
|
2) Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365: 1054-61
|
|
|
|
|
|
3) James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434: 1144-8
|
|
|
|
|
|
4) Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005; 7: 387-97
|
|
|
|
|
|
5) Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood. 2003; 101: 2534-41
|
|
|
|
|
|
6) Strupp C, Germing U, Scherer A, et al. Thalidomide for the treatment of idiopathic myelofibrosis. Eur J Haematol. 2004; 72: 52-7
|
|
|
|
|
|
7) Marchetti M, Barosi G, Balestri F, et al. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. J Clin Oncol. 2004; 22: 424-31
|
|
|
|
|
|
8) Thomas DA, Giles FJ, Albitar M, et al. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer. 2006; 106: 1974-84
|
|
|
|
|
|
9) Tefferi A, Cortes J, Verstovsek S, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006; 108: 1158-64
|
|
|
|
|
|
10) Quintas-Cardama A, Kantarjian HM, Manshouri T, et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol. 2009; 27: 4760-6
|
|
|
|
|
|
11) Jabbour E, Thomas D, Kantarjian H, et al. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. Blood. 2011; 118: 899-902
|
|
|
|
|
|
12) Tefferi A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009; 27: 4563-9
|
|
|
|
|
|
13) Passamonti F, Gattoni E, Cervantes F, et al. Pomalidomide therapy in myelofibrosis: 2-year follow up of a randomized phase 2 study [abstract]. ASH Anuual Meeting Abstracts. 2009; #1904
|
|
|
|
|
|
14) Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010; 363: 1117-27
|
|
|
|
|
|
15) Verstovsek S, Mesa R, Gotlib J, et al. Results of COMFORT-I, a randomized, double-blind phase iii trial of the JAK1 and JAK2 inhibitor Ruxolitinib (INCB018424) versus placebo for patients with myelofibrosis. European Hematology Association meeting. 2011(abstract); #0505
|
|
|
|
|
|
16) Harrison C, Kiladjian JJ, Al-Ali HK, et al. A randomized study of JAK inhibitor Ruxolitinib (INC424) vs best available therapy in primary myelofibrosis (MF), post-polycythemia vera-MF or post-essential thrombocythemia MF. European Hematology Association meeting. 2011(abstract); #1020
|
|
|
|
|
|
17) Santos F KH, Jain NJ, et al. Phase II study of CEP-701, an oral available JAK2 inhibitor, in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis [abstract]. European Hematology Association meeting. 2009
|
|
|
|
|
|
18) Hexner E, Prchal JD, Demakos EP, et al. A multicenter, open label phase I/II study of CEP701 (Lestaurtinib) in adults with myelo-fibrosis; a report on phase I: A study of the myeloproliferative disorders research consortium (MPD-RC) [abstract]. ASH Anuual Meeting Abstracts. 2009; #754
|
|
|
|
|
|
19) Pardanani AD, Gotlib JR, Jamieson C, et al. A phase I evaluation of TG101348, a selective JAK2 inhibitor, in myelofibrosis: clinical response is accompanied by significant reduction in JAK2V617F allele burden [abstract]. ASH Anuual Meeting Abstracts. 2009; #755
|
|
|
|
|
|
20) Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011; 29: 789-96
|
|
|
|
|